Skip to main content

Drug Interactions between resmetirom and sacubitril / valsartan

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

valsartan resmetirom

Applies to: sacubitril / valsartan and resmetirom

MONITOR: Coadministration with inhibitors of the hepatic uptake transporter OATP 1B1 (e.g., rifampin, cyclosporine, paritaprevir) or the hepatic efflux transporter MRP2 (e.g., ritonavir) may increase the systemic exposure to valsartan, which is a substrate of both transporters.

MANAGEMENT: Caution is advised if valsartan is used in combination with inhibitors of OATP 1B1 or MRP2. Pharmacologic response and blood pressure should be monitored more closely following the addition, discontinuation, or change of dosage of the transporter inhibitor, and the valsartan dosage adjusted as necessary.

References (7)
  1. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  3. (2007) "Product Information. Exforge (amlodipine-valsartan)." Novartis Pharmaceuticals
  4. Cerner Multum, Inc. "Australian Product Information."
  5. (2022) "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC
  6. (2020) "Product Information. Nexlizet (bempedoic acid-ezetimibe)." Esperion Therapeutics
  7. (2020) "Product Information. Nexletol (bempedoic acid)." Esperion Therapeutics
Moderate

sacubitril resmetirom

Applies to: sacubitril / valsartan and resmetirom

GENERALLY AVOID: Coadministration with inhibitors of the hepatic uptake transporters organic anion transporting polypeptides (OATP) 1B1 and/or OATP 1B3 may increase the plasma concentrations of resmetirom, which has been shown to be a substrate and inhibitor of these transporters in vitro. This may increase the risk and/or severity of resmetirom-related adverse effects (e.g., hepatotoxicity, gallbladder-related adverse reactions, diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, dizziness); however, clinical data are not available.

MANAGEMENT: According to the manufacturer of resmetirom, concomitant use with inhibitors of OATP 1B1 and/or OATP 1B3 should generally be avoided.

References (1)
  1. (2024) "Product Information. Rezdiffra (resmetirom)." Madrigal Pharmaceuticals, Inc.

Drug and food interactions

Moderate

valsartan food

Applies to: sacubitril / valsartan

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer